US FDA centennary becomes target for political jostling

9 July 2006

The US Food and Drug Administration's centennial commemorations (see page 13) have become the target of criticism, some of which draws attention to recent opinion polling, suggesting that the American public lacks confidence in the agency's effectiveness.

Sidney Wolfe, director of Public Citizen's Health Research Group, a campaigning organization, issued a statement to coincide with the FDA's celebrations. He said: "publicly, the US FDA is bragging, with good cause, about its 100 years of history that include many noteworthy accomplishments. But, like misleading prescription drug ads that frequently understate the risks while overemphasizing benefits, the FDA's 100th anniversary propaganda campaign hides and denies the many ways the agency is engaging in an unprecedented assault on the American public on behalf of its drug, device, food and other industry 'clients'."

Public "extremely concerned" about

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight